Executive Summary
PCC Rokita SA manufactures and distributes chemical products in Poland and internationally. More Details
Rewards
Risk Analysis
Snowflake Analysis
Second-rate dividend payer with imperfect balance sheet.
Similar Companies
Share Price & News
How has PCC Rokita's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: PCR is less volatile than 75% of Polish stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: PCR's weekly volatility (6%) has been stable over the past year.
Market Performance
7 Day Return
9.6%
PCR
2.0%
PL Chemicals
-0.9%
PL Market
1 Year Return
21.2%
PCR
9.6%
PL Chemicals
0.4%
PL Market
Return vs Industry: PCR exceeded the Polish Chemicals industry which returned 8.2% over the past year.
Return vs Market: PCR exceeded the Polish Market which returned 0.3% over the past year.
Shareholder returns
| PCR | Industry | Market | |
|---|---|---|---|
| 7 Day | 9.6% | 2.0% | -0.9% |
| 30 Day | 23.1% | 10.8% | 2.5% |
| 90 Day | 36.1% | 17.9% | 16.0% |
| 1 Year | 30.3%21.2% | 11.7%9.6% | 1.3%0.4% |
| 3 Year | -30.1%-45.1% | -34.6%-40.9% | -13.3%-18.6% |
| 5 Year | 108.1%39.8% | -45.0%-52.0% | 21.6%7.8% |
Long-Term Price Volatility Vs. Market
How volatile is PCC Rokita's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall St
Is PCC Rokita (WSE:PCR) Using Too Much Debt?3 weeks ago | Simply Wall St
Should We Be Excited About The Trends Of Returns At PCC Rokita (WSE:PCR)?1 month ago | Simply Wall St
Reflecting on PCC Rokita's (WSE:PCR) Share Price Returns Over The Last Three YearsValuation
Is PCC Rokita undervalued compared to its fair value and its price relative to the market?
16.73x
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: PCR (PLN61.8) is trading above our estimate of fair value (PLN26.08)
Significantly Below Fair Value: PCR is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: PCR is poor value based on its PE Ratio (16.7x) compared to the PL Chemicals industry average (15.6x).
PE vs Market: PCR is poor value based on its PE Ratio (16.7x) compared to the Polish market (13.7x).
Price to Earnings Growth Ratio
PEG Ratio: PCR is poor value based on its PEG Ratio (4.8x)
Price to Book Ratio
PB vs Industry: PCR is overvalued based on its PB Ratio (1.7x) compared to the PL Chemicals industry average (0.9x).
Next Steps
Future Growth
How is PCC Rokita forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
3.5%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PCR's forecast earnings growth (3.5% per year) is above the savings rate (2.7%).
Earnings vs Market: PCR's earnings (3.5% per year) are forecast to grow slower than the Polish market (18% per year).
High Growth Earnings: PCR's earnings are forecast to grow, but not significantly.
Revenue vs Market: PCR's revenue (3.2% per year) is forecast to grow slower than the Polish market (6% per year).
High Growth Revenue: PCR's revenue (3.2% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: PCR's Return on Equity is forecast to be low in 3 years time (8.4%).
Next Steps
Past Performance
How has PCC Rokita performed over the past 5 years?
-2.1%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: PCR has high quality earnings.
Growing Profit Margin: PCR's current net profit margins (5.2%) are lower than last year (9.5%).
Past Earnings Growth Analysis
Earnings Trend: PCR's earnings have declined by 2.1% per year over the past 5 years.
Accelerating Growth: PCR's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: PCR had negative earnings growth (-49.2%) over the past year, making it difficult to compare to the Chemicals industry average (-1.4%).
Return on Equity
High ROE: PCR's Return on Equity (10.1%) is considered low.
Next Steps
Financial Health
How is PCC Rokita's financial position?
Financial Position Analysis
Short Term Liabilities: PCR's short term assets (PLN348.3M) do not cover its short term liabilities (PLN374.1M).
Long Term Liabilities: PCR's short term assets (PLN348.3M) do not cover its long term liabilities (PLN821.8M).
Debt to Equity History and Analysis
Debt Level: PCR's debt to equity ratio (98.9%) is considered high.
Reducing Debt: PCR's debt to equity ratio has increased from 68.6% to 98.9% over the past 5 years.
Debt Coverage: PCR's debt is well covered by operating cash flow (47.3%).
Interest Coverage: PCR's interest payments on its debt are well covered by EBIT (5.8x coverage).
Balance Sheet
Next Steps
Dividend
What is PCC Rokita current dividend yield, its reliability and sustainability?
5.52%
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: PCR's dividend (5.52%) is higher than the bottom 25% of dividend payers in the Polish market (1.58%).
High Dividend: PCR's dividend (5.52%) is in the top 25% of dividend payers in the Polish market (5.13%)
Stability and Growth of Payments
Stable Dividend: PCR has been paying a dividend for less than 10 years and during this time payments have been volatile.
Growing Dividend: PCR has only been paying a dividend for 6 years, and since then payments have fallen.
Current Payout to Shareholders
Dividend Coverage: With its high payout ratio (92.3%), PCR's dividend payments are not well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: PCR's dividends in 3 years are forecast to be well covered by earnings (50% payout ratio).
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
zł4m
CEO Compensation
CEO
Wieslaw Klimkowski
no data
Tenure
zł3,948,000
Compensation
Mr. Wieslaw Klimkowski serves as the President of the Management Boards at Rokita S.A. and Silesia-Kalk Sp. z o.o. Mr. Klimkowski serves as President of the Management Board and Director of Investor Superv...
CEO Compensation Analysis
Compensation vs Market: Wieslaw's total compensation ($USD1.06M) is above average for companies of similar size in the Polish market ($USD385.84K).
Compensation vs Earnings: Wieslaw's compensation has been consistent with company performance over the past year.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
PCC Rokita SA's company bio, employee growth, exchange listings and data sources
Key Information
- Name: PCC Rokita SA
- Ticker: PCR
- Exchange: WSE
- Founded: NaN
- Industry: Specialty Chemicals
- Sector: Materials
- Market Cap: zł1.211b
- Shares outstanding: 19.85m
- Website: https://www.pcc.rokita.pl
Number of Employees
Location
- PCC Rokita SA
- ul. Sienkiewicza 4
- Brzeg Dolny
- 56-120
- Poland
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| PCR | WSE (Warsaw Stock Exchange) | Yes | Bearer Shares | PL | PLN | Jun 2014 |
| 0QVX | LSE (London Stock Exchange) | Yes | Bearer Shares | GB | PLN | Jun 2014 |
Biography
PCC Rokita SA manufactures and distributes chemical products in Poland and internationally. The company offers chloralkali, raw materials, and intermediates; polyurethanes; specialty products; and surfacta...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/01/22 18:03 |
| End of Day Share Price | 2021/01/22 00:00 |
| Earnings | 2020/09/30 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.